Image Source: Zacks Investment Research The double-blind, placebo-controlled phase III FOCUS study evaluated solriamfetol versus placebo in adults with ADHD ... The stock price decline could ...

According to the company, the U.S. trial reached the main goal, as the mean reductions of the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score from baseline in response to the ...

The double-blind, placebo-controlled phase III FOCUS study evaluated solriamfetol versus placebo in adults with ADHD. Patients were ... of the news. The stock price decline could be because ...